Here are 1-3 brief analogies for BridgeBio Oncology Therapeutics (BBOT):

• It's like a publicly traded private equity firm, but its sole mission is to find and acquire one promising private healthcare company to bring it to the stock market.

• Think of it as a corporate talent scout for the healthcare industry, specifically looking for a top-tier private company to acquire and launch onto the public stock exchange.

• It's like a "blank check" investment vehicle listed on the stock market, with a team of experts dedicated to identifying and merging with an innovative private healthcare business.

• Business Combination Vehicle: Acts as a special purpose acquisition company (SPAC) formed for the sole purpose of effecting a merger, share exchange, asset acquisition, or similar business combination with one or more target businesses.

BridgeBio Oncology Therapeutics (BBOT) is a blank check company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. As such, it does not currently have major customers that purchase products or services in the traditional sense.

Its primary activity is to identify and merge with a target company, thereby bringing that company public. At the time of the provided description, the company had not selected any specific business combination target and had not engaged in substantive discussions with potential targets.

Eli Wallace, PhD Chief Executive Officer

Eli Wallace serves as the Chief Executive Officer of BridgeBio Oncology Therapeutics (BBOT). Prior to his role as CEO, Dr. Wallace was the oncology R&D chief at BridgeBio, the parent company from which BridgeBio Oncology Therapeutics was spun out as a standalone entity.

Uneek Mehra, MBA, MMS Chief Financial Officer

Uneek Mehra was appointed Chief Financial Officer of BridgeBio Oncology Therapeutics on July 21, 2025. He brings over 28 years of global financial and business leadership experience in the biotechnology and pharmaceutical industries. Before joining BBOT, Mr. Mehra was the Chief Financial & Business Officer of 4D Molecular Therapeutics, Inc. from September 2023 to July 2025. From September 2021 to July 2023, he held the position of Chief Financial and Business Officer and Principal Financial Officer at Myovant Sciences, Ltd., which was subsequently acquired by Sumitomo Pharma.

Pedro J. Beltran, PhD Chief Scientific Officer

Pedro J. Beltran is the Chief Scientific Officer of BridgeBio Oncology Therapeutics. He previously served as the head of biology for BridgeBio's oncology unit before its transition into BridgeBio Oncology Therapeutics.

Yong (Ben) Ben, MD, MBA Chief Medical and Development Officer

Yong (Ben) Ben was appointed Chief Medical and Development Officer of BridgeBio Oncology Therapeutics in September 2024. He oversees the company's clinical programs and brings over 25 years of experience in oncology drug development, having contributed to the approval of more than 10 molecules across over 20 indications. His prior roles include Venture Partner at Eight Roads Venture, acting Chief Executive Officer of AlphaGen, Chief Medical Officer at BeiGene (solid tumors), and Chief Medical Officer at BioAtla. He also served as the Global Clinical Leader of Immuno-Oncology Clinical Development at AstraZeneca.

Bihua Chen Director

Bihua Chen serves as a Director on the Board of BridgeBio Oncology Therapeutics. She is the founder of Cormorant Asset Management, LP, an investment firm established in 2013 that focuses on biotech, MedTech, and life science companies, managing assets exceeding $3 billion. Ms. Chen manages both public and private funds for Cormorant. Prior to founding Cormorant, she managed a healthcare-focused account as a sub-adviser to a large, multi-strategy hedge fund. In the context of the SPAC that led to BBOT's public listing, Ms. Chen was the Chairperson and Chief Executive Officer of Helix Acquisition Corp. II, the special purpose acquisition company sponsored by affiliates of Cormorant. Cormorant also led the financing round for BridgeBio Oncology Therapeutics' spinout.

Key Risks for BridgeBio Oncology Therapeutics (BBOT)

1. Failure to Complete an Initial Business Combination: BridgeBio Oncology Therapeutics is a blank check company with no operational business. Its sole purpose is to identify and complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. A significant risk is that the company may not be able to identify a suitable target or complete an initial business combination within the required timeframe, which would likely result in the company's liquidation and the return of funds to its public shareholders.
2. Dependence on Management's Ability to Identify and Complete a Business Combination: The company has no operating history or established revenue streams. Its success is entirely dependent on the ability of its management team, particularly Bihua Chen and the expertise of Cormorant, to identify and successfully execute a business combination with a promising target in the healthcare or healthcare-related industries. There is no guarantee that they will be able to do so, or that any acquired business will be successful.
3. Competition for Acquisition Targets: BridgeBio Oncology Therapeutics intends to focus on healthcare or healthcare-related industries for its business combination. The market for attractive acquisition targets in these sectors is competitive, with many other blank check companies, private equity firms, and strategic buyers seeking similar opportunities. This competition could make it difficult for BBOT to find a suitable target at a fair valuation, potentially leading to overpaying or a less optimal business combination.

Clear emerging threats for BridgeBio Oncology Therapeutics (BBOT) include:

• Increased regulatory scrutiny and potential for more restrictive rules: Regulatory bodies, particularly the SEC, have intensified their oversight of Special Purpose Acquisition Companies (SPACs). Proposed rule changes could make SPACs more akin to traditional IPOs, potentially eliminating some of their perceived advantages (e.g., less stringent disclosure requirements, liability protection for forward-looking statements), thereby making the SPAC route less attractive for target companies and more complex for SPAC sponsors.
• Sustained decline in investor appetite and high redemption rates: Following a boom, the SPAC market has experienced a significant downturn, characterized by poor post-merger performance of many de-SPACed companies. This has led to a pronounced decrease in investor interest, resulting in high shareholder redemption rates during de-SPAC transactions. High redemptions reduce the capital available for the target company, making it challenging for SPACs like BBOT to complete acquisitions or to attract quality targets.
• Intensified competition for suitable targets in a challenging market: While BBOT benefits from its sponsor's expertise in life sciences, the overall market for high-quality private companies remains highly competitive. With decreased investor confidence in SPACs, private companies may increasingly prefer traditional IPOs or private funding rounds, making it more difficult for SPACs to secure desirable business combination targets at attractive valuations.

For BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, the expected drivers of future revenue growth over the next 2-3 years are centered on the successful advancement and potential commercialization of its oncology pipeline.

1. Advancement of Clinical-Stage Oncology Pipeline: A primary driver will be the successful progression of its three clinical-stage small molecule inhibitors—BBO-8520, BBO-11818, and BBO-10203—through various phases of clinical trials. These compounds target KRAS mutations and PI3Kα malignancies, and their successful development and eventual regulatory approval are fundamental to future revenue generation.
2. Positive Clinical Data Readouts and Milestones: Key catalysts for future revenue potential include positive data readouts from ongoing clinical trials. Updated clinical data for all three programs are anticipated in the second half of 2026. Such data can de-risk the assets, enhance their market value, and attract further investment or partnerships.
3. Development and Commercialization of Combination Therapies: BBOT is pursuing an internal combination strategy, aiming to achieve safe, concurrent, high-level suppression of both the MAPK and PI3Kα pathways. The successful development of these combination therapies, with internal combinations anticipated to open later in 2026, could expand the potential patient population and market opportunity for its drugs.
4. Strategic Partnerships and Licensing Agreements: As a clinical-stage company, positive clinical data could make BBOT's pipeline assets attractive for strategic partnerships or licensing agreements with larger pharmaceutical companies. These collaborations could provide non-dilutive funding through upfront payments and milestone payments, and potentially future royalty streams upon product commercialization.

Share Issuance

• BridgeBio Oncology Therapeutics experienced substantial shareholder dilution in the past year, with total shares outstanding growing by 240.4%.
• The business combination with Helix Acquisition Corp. II involved the issuance of shares, and as of March 6, 2026, the company had approximately 79.99 million shares outstanding.

Inbound Investments

• The company completed a business combination with Helix Acquisition Corp. II on August 11, 2025.
• The transaction generated approximately $382 million in gross proceeds, combining funds from the former Helix II trust account and a Private Investment in Public Equity (PIPE) financing.
• The PIPE financing, which contributed approximately $260 million, was led by Cormorant Asset Management and included other institutional investors.

Capital Expenditures

• For the full year 2025, research and development expenses increased to $121.2 million, up from $73.1 million in 2024, reflecting an aggressive investment phase for a clinical-stage oncology company.
• General and administrative costs rose to $24.6 million in 2025 from $7.8 million in 2024, attributed to expanded clinical activity and standalone operations post-SPAC transaction.
• The company ended 2025 with cash, cash equivalents, and marketable securities of $425.5 million, which management anticipates will fund operations into 2028.